Status:
RECRUITING
Biomarkers in Multiple Myeloma
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Conditions:
Hematological Patients
Newly Diagnosed Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The association between multiple myeloma (MM) and venous thromboembolism (VTE) is well known. Indeed, the incidence of VTE is increased in patients with newly diagnosed MM and in patients treated by i...
Detailed Description
There is a need to discern predictive biomarkers in order to better identify patients at risk of developing VTE, to decipher the mechanisms by which myeloma treatments interfere and in fine to choose ...
Eligibility Criteria
Inclusion
- Patient affiliated to a social security regimen or beneficiary of the same
- Signed written informed consent form
- Confirmed diagnosis of de novo multiple myeloma, non-previously treated and requiring treatment.
Exclusion
- Pregnant women
- Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent
- Refusing participation
- Patient whose follow-up or life expectancy is less than 6 months.
Key Trial Info
Start Date :
May 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 30 2027
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT05259553
Start Date
May 20 2022
End Date
October 30 2027
Last Update
April 9 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospices Civils de Lyon
Lyon, France, 69495
2
CHU de Saint-Etienne
Saint-Etienne, France, 42055